We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 12, 2023

Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma



Additional Info

Disclosure statements are available on the authors' profiles:

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study
Blood 2022 Dec 21;[EPub Ahead of Print], JS Abramson, SR Solomon, JE Arnason, PB Johnston, B Glass, V Bachanova, S Ibrahimi, S Mielke, PGNJ Mutsaers, FJ Hernandez-Ilizaliturri, K Izutsu, F Morschhauser, MA Lunning, A Crotta, S Montheard, A Previtali, K Ogasawara, M Kamdar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading